UCB granted NewBridge exclusive rights to develop and commercialize Cimzia, Vimpat and Neupro in "several" Middle East and African countries

UCB S.A.

Belgium / Mid-Cap Biopharma ($1-$50 billion)

$11,495.1m on 03/01/2013 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

NewBridge Pharmaceuticals Ltd.

UAE / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced